---
title: Continuous Glucose Monitoring (CGM) in Prediabetes With Community Based Recruitment
nct_id: NCT07477249
overall_status: RECRUITING
phase: NA
sponsor: David S Black, PhD
study_type: INTERVENTIONAL
primary_condition: Prediabetes
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07477249.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07477249"
ct_last_update_post_date: 2026-03-30
last_seen_at: "2026-05-12T07:30:46.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Continuous Glucose Monitoring (CGM) in Prediabetes With Community Based Recruitment

**Official Title:** Continuous Glucose Monitoring (CGM) in Prediabetes With Health Education Videos

**NCT ID:** [NCT07477249](https://clinicaltrials.gov/study/NCT07477249)

## Key Facts

- **Status:** RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** David S Black, PhD
- **Collaborators:** National Institute on Minority Health and Health Disparities (NIMHD)
- **Conditions:** Prediabetes
- **Start Date:** 2026-02-26
- **Completion Date:** 2027-03-30
- **CT.gov Last Update:** 2026-03-30

## Brief Summary

The objective of this project is to develop a behavioral intervention that combines wearable continuous glucose monitoring (CGM) with smartphone feedback and educational video clips generated by artificial intelligence (AI) software to improve glycemic control among individuals with pre-diabetes. The goal is to prevent transition to type 2 diabetes (T2D).

## Detailed Description

The primary objective of this new project is to enhance glycemic control in individuals with prediabetes and deter the progression to Type 2 Diabetes (T2D) within the Los Angeles (LA) County community. Our proposal involves conducting a Phase 0 intervention development study. This study will enlist a final sample of N=50 adults who speak English and/or Spanish, have non-clinical prediabetes, and test positive for prediabetes via a finger-prick A1c% screening. Participants will wear CGM devices for 20 days, with glucose data masked for the first 10 days and unmasked for the next 10 days. During the unmasked phase, participants will receive daily health education videos on their smartphones. The study will compare the duration of glucose excursions between the masked and unmasked phases to assess the impact of CGM feedback and health education on glucose regulation.

## Eligibility

- **Minimum age:** 35 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* 35 years of age or older
* Willingness to wear CGM sensor
* Prediabetes by finger prick blood A1C% or fasting glucose
* Centers for Disease Control and Prevention (CDC) prediabetes risk test score of 5 or higher or recent prediabetes diagnosis from physician

Exclusion Criteria:

* Diagnosed with any disorder that interferes with glucose
* Influential medical disorder/event affecting ability to participate in study
* Incompatible smartphone device not pairing with Dexcom G6 app
* Currently pregnant
* Previously participated in other Continuous Glucose Monitoring studies
* Having a planned trip outside California in the following 2 months
```

## Arms

- **Single Group: CGM with Masked Phase A and Unmasked Phase B** (OTHER) — Participants wear a CGM on the back of the arm. During Phase A, glucose values are not visible to participants. During Phase B, glucose values are visible via the phone app.

## Interventions

- **CGM** (DEVICE) — The CGM sensor is worn on the back of the arm and glucose levels are recorded continuously but levels are not shown on the participant's phone app in phase A.

## Primary Outcomes

- **Glucose levels** _(time frame: Maximum of 20 days of continuous wear)_ — Mean glucose in mg/dL

## Secondary Outcomes

- **Time out of range > 140 mg/dL (TOR)** _(time frame: Maximum of 20 days of continuous wear)_

## Locations (1)

- Southern California Center for Latino Health (SCCLH), Los Angeles, California, United States — _RECRUITING_

## Recent Field Changes (last 30 days)

- `results.hasResults` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `locations.southern california center for latino health (scclh)|los angeles|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07477249.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07477249*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*